teva_copy

Teva looking at up to $25 billion in bond sale to fund Allergan’s generic-unit buy – reports

pharmafile | July 15, 2016 | News story | Medical Communications, Sales and Marketing Allergan, Financial, Teva, US regulators, bond sale, deal 

Israeli drug firm Teva (NYSE: TEVA) is looking at a $20 billion to $25 billion bond sale in the US and Europe to support its $40.5 billion takeover of Botox maker Allergan’s (NYSE: AGN) generics business, according to reports.

In a filing with the US Securities and Exchange Commission the company said it will hold a series of fixed-income investor calls in the US this week and in-person meetings in Europe next week, with offerings of US dollars, euros and/or Swiss-franc-denominated multi-tranche debt securities expected to follow.

Teva indicated plans to sell up to $22 billion in bonds last year to help finance the transaction, adding it could sell as much as $7 billion in stock.

Advertisement

The company has been looking at equity and debt markets to help fund the takeover. In December, the company sold $6.75 billion shares to fund the deal.

Last year, Teva agreed to buy Allergan’s generics business for $33.75 billion in cash and $6.75 billion in stock. It’s been selling assets in a bid to gain antitrust approval.

Anjali Shukla

Related Content

Teva’s Ajovy significantly reduces migraine in children and adolescents

Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children …

Teva announces positive results from trial of AJOVY for migraine

Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …

louis-reed-pwckf7l4-no-unsplash_5

Sanofi and Teva partner for development of inflammatory bowel disease treatment

Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …

The Gateway to Local Adoption Series

Latest content